elhamkhani
/
Test2
/
Login
Register
TriplyDB
Test2
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
GraphQL
BETA
Graphs
1
Q27851967-01E8F048-4343-44D3-AD7C-058EB99D162D
Q27851967-01E8F048-4343-44D3-AD7C-058EB99D162D
BestRank
Statement
http://www.wikidata.org/entity/statement/Q27851967-01E8F048-4343-44D3-AD7C-058EB99D162D
Ponatinib in refractory Philadelphia chromosome-positive leukemias.
P2860
Q27851967-01E8F048-4343-44D3-AD7C-058EB99D162D
BestRank
Statement
http://www.wikidata.org/entity/statement/Q27851967-01E8F048-4343-44D3-AD7C-058EB99D162D
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
e0111137579888d058a86a253dad67d8ca89becd
P2860
Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION).